GSK boosts low-car­bon in­haler de­vel­op­ment with PhI­II tri­als, in­vest­ment in French man­u­fac­tur­ing fa­cil­i­ty 

GSK is tak­ing the next steps to de­vel­op a low-car­bon al­ter­na­tive to its me­tered dose in­haler (MDI), Ven­tolin, through be­gin­ning Phase III clin­i­cal tri­als next …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER